Drug intelligence / Profile preview

acitretin + calcitriol

Development stage: Preclinical
Lead developer: Allergan
Modality: Small Molecules
Administration: Oral

Overview

The combination of acitretin and oral calcitriol is used for the treatment of plaque-type psoriasis. Acitretin is a second-generation retinoid that modulates keratinocyte proliferation, reducing desquamation, erythema, and lesion thickness in psoriasis. Calcitriol is the active form of vitamin D3 (1,25-dihydroxycholecalciferol) and acts by binding to vitamin D receptors in skin cells, regulating cell differentiation and proliferation. The combination aims to enhance efficacy while potentially reducing adverse effects compared to monotherapy[1][3][9].

Other names: acitretin and calcitriolacitretin plus calcitriol

Targets

RARA (Retinoic acid receptor alpha)RAR (Retinoic acid receptor)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on acitretin + calcitriol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on acitretin + calcitriol.

Explore the full profile